About Clerkenwell Health

Our founders: Dr Henry Fisher (CSO), Tom McDonald (CEO), Sam Lewis (CFO) and George McBride (CCO)

Specialist sites built for neuropsychiatric breakthroughs

From psychedelics to the full CNS spectrum

Our first projects broke ground in the emerging field of psychedelic-assisted therapy. We opened Europe's first commercial research site dedicated to psychedelic trials, designed specifically to support patients under the effects of psychedelics with dignity and care, earning coverage in The Guardian, The Times, Evening Standard, Sifted, Forbes and more.

While psychedelics remain an important focus, our model is now transforming trials across the full spectrum of CNS and psychiatric conditions, from depression and anxiety to dementia and other neurodegenerative disorders.

Because when you design trials around human dignity, breakthrough science follows.

Why the UK?

Why the UK?

The UK has become one of the world's most supportive environments for innovative drug developers. Progressive government policies – from the Innovative Licensing and Access Pathway to streamlined regulatory submissions – make it a globally competitive location for clinical trials. With world-leading academic institutions, one of the richest healthcare datasets globally, and a growing ecosystem of pioneering drug developers, the UK is uniquely positioned for breakthroughs in CNS and mental health research.

The UK has become one of the world's most supportive environments for innovative drug developers. Progressive government policies – from the Innovative Licensing and Access Pathway to streamlined regulatory submissions – make it a globally competitive location for clinical trials. With world-leading academic institutions, one of the richest healthcare datasets globally, and a growing ecosystem of pioneering drug developers, the UK is uniquely positioned for breakthroughs in CNS and mental health research.

Looking Ahead

Looking Ahead

The next stage of our journey is bold: building a 5-site national clinical trial network across the UK.

Some of these sites will be integrated directly into NHS infrastructure – a first-of-its-kind model designed to overcome systemic challenges in patient recruitment, site performance, and trial delivery. By creating this network, we aim to make the UK the most attractive location in the world for CNS and psychiatric clinical research, where science and compassion work in harmony to create groundbreaking outcomes.

The next stage of our journey is bold: building a 5-site national clinical trial network across the UK.

Some of these sites will be integrated directly into NHS infrastructure – a first-of-its-kind model designed to overcome systemic challenges in patient recruitment, site performance, and trial delivery. By creating this network, we aim to make the UK the most attractive location in the world for CNS and psychiatric clinical research, where science and compassion work in harmony to create groundbreaking outcomes.

Sign up to hear about new studies as they open.

Register your interest

Register your interest

Patients

Current Studies

FAQs

Sponsors & CROs

Capabilities

Sites

About Us

Our Story

Team

Press

Get in Touch

Policies

Cookies

Privacy Policy

Copyright © 2025 Clerkenwell Clinics Limited. All rights reserved. Clerkenwell Health is a company registered England and Wales Company No.12568155. Our clinics hold Schedule 1-4 licences from the Home Office.